AR018113A1 - Composicion farmaceutica que comprende un inhibidor de mmp y una estatina, primera composicion farmaceutica para su uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico en un mamifero que sufre hiperlipidemia y conjunto para lograr dicho efecto - Google Patents

Composicion farmaceutica que comprende un inhibidor de mmp y una estatina, primera composicion farmaceutica para su uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico en un mamifero que sufre hiperlipidemia y conjunto para lograr dicho efecto

Info

Publication number
AR018113A1
AR018113A1 ARP990100751A ARP990100751A AR018113A1 AR 018113 A1 AR018113 A1 AR 018113A1 AR P990100751 A ARP990100751 A AR P990100751A AR P990100751 A ARP990100751 A AR P990100751A AR 018113 A1 AR018113 A1 AR 018113A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
statin
mmp inhibitor
amount
Prior art date
Application number
ARP990100751A
Other languages
English (en)
Spanish (es)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR018113A1 publication Critical patent/AR018113A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP990100751A 1998-03-17 1999-02-24 Composicion farmaceutica que comprende un inhibidor de mmp y una estatina, primera composicion farmaceutica para su uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico en un mamifero que sufre hiperlipidemia y conjunto para lograr dicho efecto AR018113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
AR018113A1 true AR018113A1 (es) 2001-10-31

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100751A AR018113A1 (es) 1998-03-17 1999-02-24 Composicion farmaceutica que comprende un inhibidor de mmp y una estatina, primera composicion farmaceutica para su uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico en un mamifero que sufre hiperlipidemia y conjunto para lograr dicho efecto

Country Status (18)

Country Link
EP (1) EP1063991A1 (fr)
JP (1) JP2002506818A (fr)
KR (1) KR20010041916A (fr)
AR (1) AR018113A1 (fr)
AU (1) AU1591699A (fr)
BR (1) BR9815745A (fr)
CA (1) CA2309588A1 (fr)
CO (1) CO5070670A1 (fr)
GT (1) GT199900039A (fr)
HN (1) HN1999000029A (fr)
MY (1) MY140504A (fr)
NZ (1) NZ505994A (fr)
PA (1) PA8469001A1 (fr)
PE (1) PE20000348A1 (fr)
SV (1) SV1999000026A (fr)
UY (1) UY25436A1 (fr)
WO (1) WO1999047138A1 (fr)
ZA (1) ZA992106B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US7816347B2 (en) 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
EP1948599A1 (fr) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Procede de preparation de sel hemicalcique d acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
US20110182851A1 (en) * 2008-07-11 2011-07-28 Jan Nilsson Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ319906A (en) * 1995-11-02 2000-02-28 Warner Lambert Co Method of preparing a pharmaceutical composition for regulating lipid concentration comprising using an acyl-CoA cholesterol O-acyltransferase inhibitor and an HMG-CoA reductase inhibitor
EE03965B1 (et) * 1996-05-17 2003-02-17 Warner-Lambert Company Maatriksi metalloproteinaasi bifenüülsulfoonamiidinhibiitorid
BR9714385A (pt) * 1996-12-09 2000-05-16 Warner Lambert Co Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
EP1063991A1 (fr) 2001-01-03
CO5070670A1 (es) 2001-08-28
CA2309588A1 (fr) 1999-09-23
NZ505994A (en) 2003-10-31
KR20010041916A (ko) 2001-05-25
PE20000348A1 (es) 2000-05-22
GT199900039A (es) 2000-09-06
ZA992106B (en) 1999-09-30
BR9815745A (pt) 2000-11-14
AU1591699A (en) 1999-10-11
JP2002506818A (ja) 2002-03-05
PA8469001A1 (es) 2002-09-17
UY25436A1 (es) 2001-10-25
SV1999000026A (es) 2000-01-18
MY140504A (en) 2009-12-31
WO1999047138A1 (fr) 1999-09-23
HN1999000029A (es) 1999-09-29

Similar Documents

Publication Publication Date Title
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2163511T3 (es) Preparacion farmaceutica conteniendo glucagon.
ES2172572T3 (es) Emulsion farmaceutica.
BR9913742A (pt) Inibidores de fator viia
BR0112519A (pt) Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
EA199700266A1 (ru) Фармацевтическая композиция, содержащая выбранные гидраты карбоната лантана
BR0111667A (pt) Novos compostos
BR0002898A (pt) Aplicador de doses de lìquido que possui um dispositivo para contar as doses ministradas
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
TW323953B (en) A pharmaceutical composition used to prevent or treat non-inflammatory-induced high intraocular pressure related to the application of steroids or endogenous steroids
ES2170918T3 (es) Inhibidor de proteina quinasa c sustituidos con halo.
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
DE50301661D1 (de) Darreichungsform von Ibuprofen-Natrium
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
FR2848116B1 (fr) Composition cosmetique comprenant un inhibiteur des metallo-proteinases et un lipopeptide.
NO985964D0 (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
ATE273699T1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
AR038143A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
AR018113A1 (es) Composicion farmaceutica que comprende un inhibidor de mmp y una estatina, primera composicion farmaceutica para su uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico en un mamifero que sufre hiperlipidemia y conjunto para lograr dicho efecto
ES2173294T3 (es) Nuevo uso medico.
ES2194933T3 (es) Inhibidores de la agregacion plaquetaria.
ES2148493T3 (es) Nuevos compuestos con efecto analgesico y anestesico local.

Legal Events

Date Code Title Description
FB Suspension of granting procedure